SVB Leerink Raises Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $230.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price target upped by analysts at SVB Leerink from $165.00 to $230.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. SVB Leerink’s price target would indicate a potential upside of 43.11% from the company’s previous close.

A number of other equities analysts have also commented on SRPT. Cantor Fitzgerald reissued a “neutral” rating and set a $128.00 price target on shares of Sarepta Therapeutics in a research note on Friday. JPMorgan Chase & Co. decreased their price objective on Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating on the stock in a research report on Friday, May 3rd. Morgan Stanley restated an “overweight” rating and set a $165.00 price objective on shares of Sarepta Therapeutics in a research report on Friday. Citigroup upped their price objective on Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Finally, Mizuho upped their price objective on Sarepta Therapeutics from $145.00 to $179.00 and gave the company a “buy” rating in a research report on Friday, May 17th. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $182.22.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $160.72 on Monday. The company has a market capitalization of $15.19 billion, a PE ratio of 1,461.09 and a beta of 0.96. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05. The business’s fifty day moving average is $125.56 and its 200 day moving average is $120.18. Sarepta Therapeutics has a fifty-two week low of $55.25 and a fifty-two week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The company had revenue of $413.50 million for the quarter, compared to the consensus estimate of $375.52 million. During the same period in the previous year, the business earned ($1.44) earnings per share. Sarepta Therapeutics’s quarterly revenue was up 63.1% compared to the same quarter last year. Sell-side analysts predict that Sarepta Therapeutics will post 2.99 earnings per share for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, insider Dallan Murray sold 3,635 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the sale, the insider now owns 18,125 shares of the company’s stock, valued at approximately $2,537,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mather Group LLC. purchased a new position in shares of Sarepta Therapeutics during the 1st quarter valued at about $28,000. Riggs Asset Managment Co. Inc. raised its stake in shares of Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 125 shares during the last quarter. New Covenant Trust Company N.A. purchased a new position in shares of Sarepta Therapeutics during the 1st quarter valued at about $32,000. Cary Street Partners Investment Advisory LLC increased its stake in shares of Sarepta Therapeutics by 154.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 154 shares in the last quarter. Finally, Principal Securities Inc. purchased a new position in shares of Sarepta Therapeutics in the 4th quarter valued at about $26,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.